Repare Therapeutics

Recent cancer treatment advancements include a stage 4 breast cancer patient achieving complete remission through immunotherapy and a Scottish woman receiving a personalized mRNA cancer vaccine. Key players in these advancements include Oncolytics Biotech Inc., Cargo Therapeutics, Inc., Immuneering Corporation, RenovoRx, Inc., and Repare Therapeutics Inc. Oncolytics Biotech highlights 2024 achievements and prepares for 2025 with promising breast and GI cancer data.

The ZEST trial, evaluating niraparib for breast cancer recurrence prevention in ctDNA-positive patients, failed due to insufficient enrollment. Lessons include starting ctDNA testing during treatment and focusing on high-risk patients. Median recurrence-free intervals were 11.4 months with niraparib vs. 5.4 months with placebo, though conclusions on efficacy are limited.

The ZEST trial, aiming to evaluate niraparib for breast cancer recurrence prevention in ctDNA-positive patients, failed to accrue enough eligible patients. Lessons include starting ctDNA testing during treatment and focusing on high-risk patients. Only 40 patients were enrolled, with insufficient data to assess niraparib efficacy.

Repare Therapeutics shares drop 47% after phase I data release. EMA recommends 17 drugs for approval, including Welireg and Emcitate. Beigene strikes $1.5B deal for MAT2A inhibitor. Bicycle Therapeutics stock drops 30% following mixed trial results. Helmholtz Institute discovers new insulin receptor. GC Biopharma to acquire Abo Holdings for ₩138B.

The ZEST trial failed to enroll enough ctDNA-positive patients for niraparib to prevent breast cancer recurrence. Lessons include starting ctDNA testing during treatment and focusing on high-risk patients. Only 40 patients were enrolled, with niraparib showing a median recurrence-free interval of 11.4 months vs. 5.4 for placebo.

Repare Therapeutics reported positive MYTHIC Phase 1 trial data for lunresertib and camonsertib combination, showing 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of gynecologic cancer patients maintained progression-free survival at 24 weeks. A registrational Phase 3 trial in endometrial cancer is planned for 2H 2025.

Repare Therapeutics' shares dropped over 38% after Phase 1 study results showed mixed efficacy and safety issues with its combination medication for endometrial and platinum-resistant ovarian cancers. The study reported response rates of 25.9% and 37.5% respectively, but 26.9% of subjects experienced Grade 3 adverse events. Despite plans for a Phase 3 study in 2025, investor concerns led to a significant stock price decline.

Repare Therapeutics reported positive Phase I MYTHIC trial data for Lunre+Camo, showing 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of gynecologic cancer patients maintained progression-free survival at 24 weeks. The company plans a registrational Phase III trial for endometrial cancer by 2025.